BWAY
BrainsWay Ltd.
$13.57
$0.00(0.00%)
35
Overall
20
Value
50
Tech
--
Quality
Market Cap
$1.00B
Volume
248.10K
52W Range
$3.92 - $14.65
Target Price
$15.33
Company Overview
| Mkt Cap | $1.00B | Price | $13.57 |
| Volume | 248.10K | Change | +0.00% |
| P/E Ratio | 343.9 | Open | $13.65 |
| Revenue | $41.0M | Prev Close | $13.57 |
| Net Income | $2.9M | 52W Range | $3.92 - $14.65 |
| Div Yield | N/A | Target | $15.33 |
| Overall | 35 | Value | 20 |
| Quality | -- | Technical | 50 |
No chart data available
About BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Sector: Healthcare
Industry: Diagnostics & Research
Latest News
BrainsWay Posts Record 2025 Results and Issues Bullish 2026 Outlook on Deep TMS Momentum
TipRanks Auto-Generated Newsdesk•25 days ago
Brainsway’s New Deep TMS Depression Study Completion: What Investors Should Watch Next
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BWAY | $13.57 | 0% | 248.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |